Dr. Ramakrishnan on Advancements With CAR T-cell Therapies in LBCL

In Partnership With:

Partner | Cancer Centers | <b>UT Southwestern Harold C. Simmons Comprehensive Cancer Center </b>

Praveen Ramakrishnan, MD, MS, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma.

Praveen Ramakrishnan, MD, MS, assistant professor, the Department of Internal Medicine, UT Southwestern Medical Center, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma (LBCL).

After little progress was made in the treatment of diffuse large B-cell lymphoma for about a decade, the previous few years have presented key developments in the space, Ramakrishnan says. Novel biology-based strategies and advancements in cell therapies have given patients with LBCL a second opportunity to receive effective treatment, Ramakrishnan explains.

Although CAR T-cell therapy has shifted the needle in LBCL, more work needs to be done, Ramakrishnan continues. Additional research into CAR T-cell therapy in the future will further assist in understanding the biology of LBCL and how to best sequence therapies for patients, Ramakrishnan concludes.